Rajesh Devraj (@r_devraj) profile picture

CEO, Rectify Pharma. Venture Partner, Atlas Venture. Experienced drug hunter, company builder, entrepreneur, recovering large pharma exec.

Joined December 2013
Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)Photo by Rajesh Devraj (@r_devraj)
Rajesh Devraj retweeted
Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All
534
1,068
388
14,433
1,768,924
Rajesh Devraj retweeted
We’re heading to @AASLDtweets #TLM26! We look forward to presenting translational data on our clinical candidate RTY-406, as a transformative therapy for hepatobiliary diseases, including PSC, PBC, and genetically associated chronic cholestasis. Read more: bit.ly/3VTqqcx
1
1
47
Rajesh Devraj retweeted
Mike 3 things to consider 1) Revenue growth as modeled by sell side analysts and others is not equal to what is in the models of people who actually own stock and trade it, long buy side active funds 2) Pharma equity trades on an earnings multiple not a revenue multiple, margin expansion vs contraction can also explain “above or below” this line and 3) Terminal value assumptions matter - Organizations and management teams that have consistently demonstrated the ability to deliver organic R&D (Vertex) or BD (Abbvie) productivity get rewarded with a management premium/increased terminal value because the bet is they will do it again.
10
18
5
271
32,319
Rajesh Devraj retweeted
We Must Pace the Frontier: I’ve written a new essay on why the AI industry should slow down, with a three-part plan for doing so. Anthropic is unilaterally committing to the first of these steps. We’ll provide third-party evaluators with permanent, employee-level access to our systems, so that they can verify adherence to our safety measures, report on incidents, and assess models’ alignment during training. You can read the full post here: darioamodei.com/post/we-must…
10,542
16,298
11,365
87,514
77,146,310
Rajesh Devraj retweeted
The perfect man was delightfully imperfect. My story. insidetennis.com/2026/08/rog…
Roger Federer's Hall of Fame speech mirrored his career: long (28 minutes), gave the illusion of perfect, but it was the cracks and the tears that made it raw, real, relatable. Once again, so glad I chose him as my idol and my role model when I was a kid. youtube.com/watch?v=fQXTNAnY…
2
2
31
2,052
Rajesh Devraj retweeted
Roger Federer's COMPLETE @TennisHalloFame Induction speech. Stop what you are doing and enjoy this half an hour.
59
1,333
130
7,112
310,167
Rajesh Devraj retweeted
Roger Federer's Hall of Fame speech mirrored his career: long (28 minutes), gave the illusion of perfect, but it was the cracks and the tears that made it raw, real, relatable. Once again, so glad I chose him as my idol and my role model when I was a kid. youtube.com/watch?v=fQXTNAnY…
22
322
23
2,049
77,653
Rajesh Devraj retweeted
Time to re-think the way we approve drugs for mental health. Depression kills thousands, yet we wont do conditional approval of safe compounds that work but have high placebo effects. But we approve peptides with zero data.
7
7
1
71
9,106
Rajesh Devraj retweeted
Patient-first, America-first: The Case For Global Collaboration While the rise of Chinese biopharma in the past decade has been meteoric, I’m firmly in the camp that their engagement in the global ecosystem is good for the sector – its more opportunity than threat, great for patients, and is a healthy forcing function to raise the game for everyone lifescivc.com/2026/06/patien…
3
4
3
49
23,945
American science is at risk. Biopharma leaders with Trump’s ear: don’t let bootlicking become the methods section and sycophancy the new peer review. Use your influence. Make the call. Save science. biocentury.com/article/65961…
8
10
4
64
21,235
Rajesh Devraj retweeted
An appeal to @realDonaldTrump from those of us developing potentially life changing medicines. The next @US_FDA commissioner should have: deep regulatory experience, a track record of reform, and the ability to lead a scientific institution under political & competitive pressure without compromising speed or rigor nopatientleftbehind.org/fda-… Rick Pazdur is one exemplary candidate and the industry looks forward to supporting whoever is appointed. Thanks to @NPLB_org & @PeterKolchinsky for initiating - please sign & share.
5
21
4
86
11,836
Rajesh Devraj retweeted
Our new publication in Liver International Communications demonstrates how partial loss of ABCB4 function causes toxic bile composition and drives inflammation, fibrosis and liver injury. Read more: bit.ly/48ofBSW
1
1
1
308
Rajesh Devraj retweeted
unfort the below is not surprising. we know from our gene therapy investments that to meet fda manufacturing standards for a cell or gene therapy product the absolute bare minimum spend is $50m a year just to maintain the team and manufacturing capabilities you need to check the necessary boxes. that doesn't count the direct costs of actually making and developing a drug (materials, trials, etc).
1
11
1
48
14,645
Rajesh Devraj retweeted
As someone who has covered cancer drug development for 25 years, one of the few things I am sure of is that the odds of technology folks thinking they understand biology are much higher than the odds they actually do.
This is totally out of control: There’s 0 - I repeat 0 - evidence any of the LLM work did anything meaningful for Rosie’s cancer I’m sorry to rain on the parade here. I know we want to believe. But, it’s possible to do a lot of things and have nothing happen @paul_conyngham co-administered α-PD-1 (conventional immunotherapy) with a TKI and the mRNA. It’s probably the most effective cancer immunotherapy of all time. This isn’t a small detail! There’s no evidence his process (beyond FDA approved doggie α-PD-1) had any impact on disease progression. The most parsimonious explanation is a partial response to α-PD-1 I get it. The chat bots make for a great story (although checking multiple LLMs isn’t validation), but it’s really just a neat story. It’s fundraising copy. Before he starts selling the “custom neoantigen mRNA vax” story to consumers, he should provide some evidence it did anything! That’s responsible citizen science This is just storytelling for the AGI true believers. Specifically, a story in search of venture money
12
36
7
284
48,227
Rajesh Devraj retweeted
#PrimarySclerosingCholangitis brings daily uncertainty and complex challenges for patients and caregivers. Supporting and advocating for this community is essential. Learn more about our work in #PSC: bit.ly/3V5Vul7
1
1
39
Big thank you to @r_devraj, Victoria Fort, Greg Frost, and Rachel Humphrey for an outstanding panel discussion on pipeline prioritization at the Longwood Healthcare Leaders #MiamiCEO meeting. Inspiring conversation about how we can focus innovation and resources on developing transformational medicines that make a real difference for patients.
2
1
22
836
Rajesh Devraj retweeted
I don't know how to ask for a moment of silence amid the madness that is X. But please take a moment to reflect on the heroism of William Foege. Foege, who died Saturday at 89, was a key architect of the eradication of smallpox using the vaccine. This is one of humanity's great victories over a terrible disease and a triumph of science. If you haven't, go order or download his book, "House on Fire," which chronicles that epic fight. He was head of the CDC from 1977 to 1983. He was a towering, six-foot-seven reminder that rationality can win against scourges that have beset mankind for all of history.
127
3,017
71
14,342
247,866
Rajesh Devraj retweeted
Today our CEO @r_devraj shared his perspective on the 2026 healthcare & biotech venture outlook in @WSJ ProVenture newsletter, pointing to renewed market confidence, greater focus on de-risked assets, reopening of M&A & IPOs, and regulatory uncertainty as a key challenge.
1
3
150
Completely agree w/ @NoubarAfeyan! “We are living simultaneously in the utopian age in which a baby born with a genetic death sentence is given a new lease on life thanks to the miracle of gene editing, and the dystopia in which a disease like measles is on the march in the United States” We must win with science!
2
7
50
8,403